Table 3.

Concurdance of IFOBT and Tf tests in fecal samples from colorectal cancer patients, premalignant subjects, and low-risk subjects (n = 110)

Tf (+)Tf (−)Total
A. Colorectal cancer (n = 40)
IFOBT (+)26 (65.0%)4 (10.0%)30
IFOBT (−)6 (15.0%)4 (10.0%)10
Total32840
B. Premalignant lesions (n = 36)*
IFOBT (+)14 (38.9%)2 (5.6%)16
IFOBT (−)12 (33.3%)8 (22.2%)20
Total261036
C. Low risk (n = 34)
IFOBT (+)2 (5.0%)2 (5.0%)4
IFOBT (−)6 (15.0%)24 (60.0%)30
Total82640
  • *P < 0.05 by McNemar's test.